Abstract
Interleukin-15 (IL-15) can promote both innate and adaptive immune reactions by stimulating CD8+/CD4+ T cells and natural killer cells (NK) while showing no effect in activating T-regulatory (Treg) cells or inducing activation-associated death among effector T cells and NK cells. Thus, IL-15 is considered as one of the most promising molecules for antitumor immune therapy. To improve the drug-like properties of natural IL-15, we create an IL-15-based molecule, named P22339, with the following characteristics: 1) building a complex of IL-15 and the Sushi domain of IL-15 receptor α chain to enhance the agonist activity of IL-15 via transpresentation; 2) through a rational structure-based design, creating a disulfide bond linking the IL-15/Sushi domain complex with an IgG1 Fc to augment its half-life. P22339 demonstrates excellent developability, pharmacokinetic and pharmacodynamic properties as well as antitumor efficacy in both in vitro assessments and in vivo studies. It significantly suppresses tumor growth and metastasis in rodent models, and activates T effector cells and NK cells in cynomolgus monkey. Overall, these data suggest that P22339 has a great potential for cancer immunotherapy.
References
May 13, 1994·Science·K H GrabsteinM Ahdieh
Oct 1, 1996·Nature Biotechnology·Y ReiterI Pastan
Jun 22, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists· Wei XqF Y Liew
Jul 24, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·H AraseL L Lanier
Nov 15, 2005·The Journal of Biological Chemistry·Erwan MortierYannick Jacques
Jun 8, 2006·Proceedings of the National Academy of Sciences of the United States of America·Mark P RubinsteinJonathan Sprent
Jul 27, 2006·Nature Reviews. Immunology·Thomas A Waldmann
Oct 24, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Thomas A StoklasekLeo Lefrançois
Jul 24, 2007·Nature Immunology·Mami ChirifuShinji Ikemizu
Oct 20, 2007·The Journal of Biological Chemistry·Shaun K OlsenShigeyuki Yokoyama
Feb 6, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sigrid DuboisJürgen R Müller
Mar 28, 2008·Immunological Reviews·Martin A Cheever
May 14, 2009·Protein Expression and Purification·Alison WardPhilip R Mallinder
Jun 6, 2009·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Roland E Kontermann
Sep 3, 2009·Molecular Cancer Therapeutics·Anne BessardYannick Jacques
Oct 25, 2011·Cytokine·Kai-ping HanHing C Wong
Nov 22, 2011·Protein Engineering, Design & Selection : PEDS·Wenhai LiuIra Pastan
Oct 30, 2012·Nature Immunology·Aaron M RingK Christopher Garcia
Dec 3, 2013·FEBS Letters·Alan A DombkowskiDouglas B Craig
Jan 10, 2014·Oncoimmunology·Hing C WongPeter R Rhode
Jul 20, 2014·Biochimica Et Biophysica Acta·Yoshihisa Hagihara, Dirk Saerens
Oct 13, 2014·Cytokine & Growth Factor Reviews·Johan M J Van den BerghEvelien L J M Smits
Oct 30, 2015·Cancer Immunology Research·Peter R RhodeHing C Wong
Citations
Aug 20, 2019·Immunotherapy·Faezeh GhaemdoustNima Rezaei
Dec 21, 2018·Frontiers in Immunology·Cordelia ManickamR Keith Reeves
Apr 26, 2019·International Journal of Molecular Sciences·Joana R LériasMarkus Maeurer
Feb 23, 2020·Biomolecules·Jian WangLin Sun
Mar 30, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sarah A WeissMario Sznol
Jan 1, 2021·International Immunopharmacology·Shuling ZhangFengping Shan
May 1, 2021·Cancers·Fei-Ting HsuKeng-Li Lan
Feb 27, 2021·Molecular Cancer Therapeutics·Riccardo CorbellariRoberto De Luca
May 6, 2021·Cells·Rasa IslamAlan Trounson
May 20, 2021·Nature Reviews. Clinical Oncology·Ignacio MeleroAurelien Marabelle
Aug 28, 2021·Cancers·Van Anh Do-ThiYoung Sang Kim
Feb 25, 2019·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Meiqi ZhaoJianwei Zhu